{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:40:10Z","timestamp":1716586810028},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aim:<\/jats:title>\n            <jats:p>To make an accurate estimation of the association of ERCC1 and ERCC2 polymorphisms with osteosarcoma (OS) prognosis in Chinese population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Total 7 qualified studies with 1404 osteosarcoma patients were included. Odds ratios (OR) with 95% CIs were pooled for the survival rate in different osteosarcoma patients with ERCC1 and ERCC2 genetic polymorphisms. The heterogeneity was assessed by I<jats:sup>2<\/jats:sup> test. Potential publication bias was assessed by Begg funnel plot and Egger linear regression test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In rs11615, no significant association was found under dominant [TT+TC vs. CC: OR\u200a=\u200a1.252, 95% CI:0.864\u20131.815, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.235], recessive [TT vs. TC+CC: OR\u200a=\u200a0.850, 95% CI: 0.695\u20131.030, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.095] or allelic model [T vs. C Allele: OR\u200a=\u200a1.219, 95% CI: 0.922\u20131.612, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.165]. In rs13181, no significant association was found under dominant [AA+AC vs. CC: OR\u200a=\u200a1.031, 95% CI: 0.800\u20131.329, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.801], recessive [AA vs. AC+CC: OR\u200a=\u200a1.005, 95% CI: 0.875, 1.154, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.944] or allelic model [A vs. C Allele: OR\u200a=\u200a1.009, 95% CI: 0.903\u20131.128, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.870]. In rs1799793, no significant association was found under dominant [GG+GA vs. AA: OR\u200a=\u200a1.134, 95% CI: 0.884\u20131.454, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.322, recessive [GG vs. AG+AA: OR\u200a=\u200a1.025, 95% CI: 0.881\u20131.192, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.750], or allelic model [G vs. A Allele: OR\u200a=\u200a1.046, 95% CI: 0.930\u20131.177, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.450].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013358","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T18:09:10Z","timestamp":1544292550000},"page":"e13358","source":"Crossref","is-referenced-by-count":0,"title":["Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy"],"prefix":"10.1097","volume":"97","author":[{"given":"Dabiao","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Zhenjiang No.4 Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Jiangsu Vocational College of Medicine, Zhenjiang, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20240524","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/08880010590935257","article-title":"Pediatric osteosarcoma: a 35-year experience in Slovenia","volume":"22","author":"Kuhelj","year":"2005","journal-title":"Pediatr Hematol Oncol"},{"key":"R2-20240524","doi-asserted-by":"crossref","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","volume":"21","author":"Ritter","year":"2010","journal-title":"Ann Oncol"},{"key":"R3-20240524","first-page":"121","article-title":"Incidence, and gender, age and ethnic distribution of sarcomas in the republic of suriname from 1980 to 2008","volume":"63","author":"Mans","year":"2014","journal-title":"West Indian Med J"},{"key":"R4-20240524","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7555\/JBR.30.20150075","article-title":"Molecular pathogenesis and therapeutic strategies of human osteosarcoma","volume":"30","author":"Denduluri","year":"2016","journal-title":"J Biomed Res"},{"key":"R5-20240524","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14728214.2010.505603","article-title":"Emerging drugs for high-grade osteosarcoma","volume":"15","author":"Hattinger","year":"2010","journal-title":"Expert Opin Emerg Drugs"},{"key":"R6-20240524","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e32832e0ed7","article-title":"Platinum pathway","volume":"19","author":"Marsh","year":"2009","journal-title":"Pharmacogenet Genom"},{"key":"R7-20240524","first-page":"4106","article-title":"Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer","volume":"8","author":"Yu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R8-20240524","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canep.2014.12.009","article-title":"Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma","volume":"39","author":"Goricar","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"R9-20240524","first-page":"894","article-title":"Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma","volume":"8","author":"Ji","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R10-20240524","doi-asserted-by":"crossref","first-page":"11235","DOI":"10.4238\/2015.September.22.17","article-title":"Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma","volume":"14","author":"Zhang","year":"2015","journal-title":"Genet Mol Res"},{"key":"R11-20240524","doi-asserted-by":"crossref","first-page":"11652","DOI":"10.4238\/2015.September.28.17","article-title":"Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma","volume":"14","author":"Wang","year":"2015","journal-title":"Genet Mol Res"},{"key":"R12-20240524","doi-asserted-by":"crossref","first-page":"10145","DOI":"10.4238\/2015.August.21.21","article-title":"Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma","volume":"14","author":"Cao","year":"2015","journal-title":"Genet Mol Res"},{"key":"R13-20240524","first-page":"7905","article-title":"Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma","volume":"8","author":"Sun","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R14-20240524","doi-asserted-by":"crossref","first-page":"12967","DOI":"10.4238\/2015.October.21.17","article-title":"Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma","volume":"14","author":"Liu","year":"2015","journal-title":"Genet Mol Res"},{"key":"R15-20240524","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1007\/s13277-014-2322-1","article-title":"ERCC polymorphisms and prognosis of patients with osteosarcoma","volume":"35","author":"Li","year":"2014","journal-title":"Tumour Biol"},{"key":"R16-20240524","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/107327480801500103","article-title":"Orthopedic surgery options for the treatment of primary osteosarcoma","volume":"15","author":"Marulanda","year":"2008","journal-title":"Cancer Control"},{"key":"R17-20240524","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1081\/CNV-100102557","article-title":"Current treatment of osteosarcoma","volume":"19","author":"Ferguson","year":"2001","journal-title":"Cancer Invest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812070-00037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:00:41Z","timestamp":1716584441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812070-00037"}},"subtitle":["A meta-analysis in Chinese population"],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":17,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013358","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}